Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00081588




Registration number
NCT00081588
Ethics application status
Date submitted
15/04/2004
Date registered
19/04/2004
Date last updated
20/06/2014

Titles & IDs
Public title
An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.
Scientific title
An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.
Secondary ID [1] 0 0
TMC114-C215
Secondary ID [2] 0 0
CR006724
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
HIV Infection 0 0
Condition category
Condition code
Infection 0 0 0 0
Acquired immune deficiency syndrome (AIDS / HIV)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TMC114

Experimental: 001 - TMC114600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available


Treatment: Drugs: TMC114
600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The primary parameter is the confirmed virologic response at Week 24 (a drop in viral load (copies/mL) of at least 1 log10 versus baseline.
Timepoint [1] 0 0
24 weeks
Secondary outcome [1] 0 0
Proportion of patients with a virologic response; with plasma HIV-1 RNA levels < 50 copies/mL; with plasma HIV-1 RNA levels < 400 copies/mL; Time to loss of virologic response over 144 week treatment period; Change in plasma viral load at all time points
Timepoint [1] 0 0
144 weeks

Eligibility
Key inclusion criteria
- Previous participation in the TMC114-C202 or TMC114-C213 trials

- Significant virologic failure during participation in the above trials

- Study participation in the treatment phase of the original trial for a total of at
least 12 weeks before TMC114-C215 screening

- Patient agrees to take TMC114/RTV with at least 2 other antiretrovirals (NRTIs), with
or without T-20, from baseline onwards

- Patient has given informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Use of disallowed concomitant therapy

- Patient with clinical or laboratory evidence of active liver disease, liver
impairment/ dysfunction or cirrhosis irrespective of liver enzyme levels

- Any active or unstable medical condition that, in the investigator's opinion, would
compromise the subject's safety

- Patient with laboratory abnormalities at screening as defined by ACTG grading scheme
as listed in the protocol

- Patient withdrawing consent from TMC114-C202 or TMC114-C213

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2003
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2008
Sample size
Target
Accrual to date
Final
555
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Darlinghurst
Recruitment hospital [2] 0 0
- Melbourne
Recruitment hospital [3] 0 0
- Perth
Recruitment postcode(s) [1] 0 0
- Darlinghurst
Recruitment postcode(s) [2] 0 0
- Melbourne
Recruitment postcode(s) [3] 0 0
- Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Austria
State/province [16] 0 0
Vienna
Country [17] 0 0
Austria
State/province [17] 0 0
Wien
Country [18] 0 0
Belgium
State/province [18] 0 0
Brussels
Country [19] 0 0
Belgium
State/province [19] 0 0
Brussel
Country [20] 0 0
Belgium
State/province [20] 0 0
Gent
Country [21] 0 0
Brazil
State/province [21] 0 0
Campinas
Country [22] 0 0
Brazil
State/province [22] 0 0
Curitiba
Country [23] 0 0
Brazil
State/province [23] 0 0
Rio De Janeiro
Country [24] 0 0
Brazil
State/province [24] 0 0
Sao Paulo
Country [25] 0 0
Canada
State/province [25] 0 0
Alberta
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
France
State/province [28] 0 0
Le Kremlin Bicetre
Country [29] 0 0
France
State/province [29] 0 0
Montpellier
Country [30] 0 0
France
State/province [30] 0 0
Nantes
Country [31] 0 0
France
State/province [31] 0 0
Paris Cedex 10
Country [32] 0 0
France
State/province [32] 0 0
Paris Cedex 12
Country [33] 0 0
France
State/province [33] 0 0
Paris
Country [34] 0 0
France
State/province [34] 0 0
Toulon
Country [35] 0 0
France
State/province [35] 0 0
Villejuif Cedex
Country [36] 0 0
Germany
State/province [36] 0 0
Berlin
Country [37] 0 0
Germany
State/province [37] 0 0
Bonn
Country [38] 0 0
Germany
State/province [38] 0 0
Düsseldorf
Country [39] 0 0
Germany
State/province [39] 0 0
Essen
Country [40] 0 0
Germany
State/province [40] 0 0
Freiburg
Country [41] 0 0
Germany
State/province [41] 0 0
Hamburg
Country [42] 0 0
Germany
State/province [42] 0 0
Kÿln
Country [43] 0 0
Germany
State/province [43] 0 0
Mannheim
Country [44] 0 0
Germany
State/province [44] 0 0
Munich
Country [45] 0 0
Hungary
State/province [45] 0 0
Budapest
Country [46] 0 0
Portugal
State/province [46] 0 0
Lisboa
Country [47] 0 0
Portugal
State/province [47] 0 0
Porto
Country [48] 0 0
Spain
State/province [48] 0 0
Barakaldo Vizcaya S/N
Country [49] 0 0
Spain
State/province [49] 0 0
Barcelona N/A
Country [50] 0 0
Spain
State/province [50] 0 0
Madrid
Country [51] 0 0
United Kingdom
State/province [51] 0 0
Edinburgh
Country [52] 0 0
United Kingdom
State/province [52] 0 0
London
Country [53] 0 0
United Kingdom
State/province [53] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Tibotec Pharmaceuticals, Ireland
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of the TMC114-C215 study is to evaluate the safety and tolerability of
TMC114/RTV over time. The secondary objectives are to evaluate the antiviral activity over
time and to evaluate the immunological effect over time.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00081588
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Tibotec Pharmaceuticals Clinical Trial
Address 0 0
Tibotec Pharmaceutical Limited
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00081588